Telix Pharmaceuticals (TLX) Q3 2026 TU earnings summary

Executive summary

• Q3 2026 revenue reached US$245M, up 19% YoY; strong September sales supported a higher exit rate and demand for PSMA imaging products.

• FDA approval of Pixclara added the first U.S.-approved imaging agent for glioma; BiPASS completed enrollment and received FDA Fast Track Designation.

• FY 2026 revenue and other income are expected to exceed US$1B, with revenue tracking toward the upper end of guidance.

Financial highlights

• Group revenue was US$245M versus US$206M in Q3 2025, up 19% YoY and down 1% QoQ.

• Precision Medicine revenue was US$201M versus US$155M, up 30% YoY and flat QoQ.

• TMS third-party revenue was US$44M versus US$47M, down 6% YoY and 2% QoQ.

Outlook and guidance

• FY 2026 revenue and other income expected to exceed US$1B; revenue is tracking toward the upper end of US$950M–US$970M guidance, plus US$40M other income.

• Revenue guidance includes a full-year RLS contribution and anticipated Pixclara sales in markets with marketing authorization.

• FY 2026 R&D expenditure guidance revised to US$240M–US$260M from US$230M–US$270M, subject to planned clinical, regulatory and development milestones.

• Management expects over 25% Precision Medicine revenue growth in 2026, supported by strong demand and September exit run rate.